These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34909720)

  • 41. The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.
    Langley RG; Feldman SR; Nyirady J; van de Kerkhof P; Papavassilis C
    J Dermatolog Treat; 2015 Feb; 26(1):23-31. PubMed ID: 24354461
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of Systemic Therapies in Patients with Obesity and Psoriasis: A Single-center Retrospective Study.
    Bonifati C; Capoccia R; Graceffa D; Morrone A
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):88-93. PubMed ID: 34477074
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Geographical variation and migration analysis of height, weight and body mass index in a British cohort study.
    Krzyżanowska M; Mascie-Taylor CG
    J Biosoc Sci; 2011 Nov; 43(6):733-49. PubMed ID: 21794200
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.
    Bronckers IMGJ; Paller AS; West DP; Lara-Corrales I; Tollefson MM; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Blume-Peytavi U; Szalai Z; Vleugels RA; Holland K; Murphy R; Puig L; Cordoro KM; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Seyger MMB;
    JAMA Dermatol; 2020 Apr; 156(4):384-392. PubMed ID: 32022846
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece.
    Petridis A; Panagakis P; Moustou E; Vergou T; Kallidis P; Mandekou-Lefaki I; Chaidemenos G; Sotiriadis D; Alexopoulou G; Haratsis Y; Antoniou C
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):768-775. PubMed ID: 29356149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry.
    Piaserico S; Cazzaniga S; Chimenti S; Giannetti A; Maccarone M; Picardo M; Peserico A; Naldi L;
    J Am Acad Dermatol; 2014 Feb; 70(2):257-62.e3. PubMed ID: 24355410
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
    Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
    Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry.
    Jungo P; Maul JT; Djamei V; von Felten S; Kolios AGA; Czernielewsk J; Yawalkar N; Odermatt O; Laffitte E; Anliker M; Streit M; Augustin M; Conrad C; Hafner J; Boehncke WH; Gilliet M; Itin P; French LE; Navarini AA; Häusermann P
    Dermatology; 2016; 232(6):655-663. PubMed ID: 28103601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
    Foley P; Gordon K; Griffiths CEM; Wasfi Y; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
    JAMA Dermatol; 2018 Jun; 154(6):676-683. PubMed ID: 29799960
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
    Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
    Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry.
    Callis Duffin K; Mason MA; Gordon K; Harrison RW; Crabtree MM; Guana A; Germino R; Lebwohl M
    Dermatology; 2021; 237(1):46-55. PubMed ID: 31962340
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment patterns and therapy effectiveness in psoriasis patients initiating biologic therapy in England.
    Khalid JM; Fox KM; Globe G; Maguire A; Chau D
    J Dermatolog Treat; 2014 Feb; 25(1):67-72. PubMed ID: 23336246
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy.
    Bardazzi F; Balestri R; Baldi E; Antonucci A; De Tommaso S; Patrizi A
    Dermatol Ther; 2010; 23 Suppl 1():S14-9. PubMed ID: 20136916
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    Am J Clin Dermatol; 2017 Aug; 18(4):583-590. PubMed ID: 28342016
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Geography, Race/Ethnicity, and Obesity Among Men in the United States.
    Kelley EA; Bowie JV; Griffith DM; Bruce M; Hill S; Thorpe RJ
    Am J Mens Health; 2016 May; 10(3):228-36. PubMed ID: 25567236
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Geographic tongue clinical response in moderate-to-severe psoriatic patients undergoing secukinumab: a real-life, multicenter retrospective observational study.
    Damiani G; Pacifico A; Malagoli P; Bindi M; Maiorana C; Poli P; Taschieri S; Francetti L; Corbella S; Del Fabbro M; Marino S; Spadari F; Bragazzi NL; Pigatto PDM
    J Biol Regul Homeost Agents; 2021; 35(2 Suppl. 1):331-337. PubMed ID: 34281329
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data.
    Cassano N; Galluccio A; De Simone C; Loconsole F; Massimino SD; Plumari A; Dattola S; Puglisi Guerra A; Donato L; Cantoresi F; De Pita O; Fenizi G; Altamura V; Congedo M; Pellicano R; Vena GA
    J Biol Regul Homeost Agents; 2008; 22(4):233-7. PubMed ID: 19036225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.